These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29991490)

  • 1. Cladribine: mechanisms and mysteries in multiple sclerosis.
    Jacobs BM; Ammoscato F; Giovannoni G; Baker D; Schmierer K
    J Neurol Neurosurg Psychiatry; 2018 Dec; 89(12):1266-1271. PubMed ID: 29991490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of cladribine treatment in multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Mult Scler; 1996 Jul; 1(6):343-7. PubMed ID: 9345414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential mechanisms of action related to the efficacy and safety of cladribine.
    Baker D; Pryce G; Herrod SS; Schmierer K
    Mult Scler Relat Disord; 2019 May; 30():176-186. PubMed ID: 30785074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
    Mitosek-Szewczyk K; Tabarkiewicz J; Wilczynska B; Lobejko K; Berbecki J; Nastaj M; Dworzanska E; Kolodziejczyk B; Stelmasiak Z; Rolinski J
    J Neurol Sci; 2013 Sep; 332(1-2):35-40. PubMed ID: 23835090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
    Giovannoni G
    Neurotherapeutics; 2017 Oct; 14(4):874-887. PubMed ID: 29168160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results].
    Grieb P; Stelmasiak Z
    Neurol Neurochir Pol; 1995; 29(1):69-76. PubMed ID: 7596480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
    Ceronie B; Jacobs BM; Baker D; Dubuisson N; Mao Z; Ammoscato F; Lock H; Longhurst HJ; Giovannoni G; Schmierer K
    J Neurol; 2018 May; 265(5):1199-1209. PubMed ID: 29550884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
    Laugel B; Borlat F; Galibert L; Vicari A; Weissert R; Chvatchko Y; Bruniquel D
    J Neuroimmunol; 2011 Dec; 240-241():52-7. PubMed ID: 22035961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine.
    Biernacki T; Sandi D; Bencsik K; Vécsei L
    Mini Rev Med Chem; 2020; 20(4):269-285. PubMed ID: 31644403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cladribine for multiple sclerosis: review and current status.
    Sipe JC
    Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of oral cladribine for the treatment of multiple sclerosis.
    Hartung HP; Aktas O; Kieseier B; Giancarlo Comi GC
    J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cladribine. Ortho Biotech Inc.
    Tortorella C; Rovaris M; Filippi M
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1751-6. PubMed ID: 11892941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP; Weissert R
    Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T; Torkildsen Ø; Myhr KM
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis.
    Selby R; Brandwein J; O'Connor P
    Can J Neurol Sci; 1998 Nov; 25(4):295-9. PubMed ID: 9827230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K; Sipe JC
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.